Kidney Disease, ChronicNCT05774392
An Observational Study of Patients With Chronic Kidney Disease
An observational study of Kidney Disease, Chronic and End Stage Kidney Disease, run by Target PharmaSolutions, Inc..
Trial summary
TARGET-KIDNEY is an observational research study to conduct a comprehensive review of outcomes for patients with chronic kidney disease (CKD) and end-stage renal disease (ESKD). Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Kidney Disease, Chronic, End Stage Kidney Disease
- What is being tested?
- Observational
- How many people
- 0 participants
- Where
- No sites listed yet
- Study dates
- Apr 2025to 7 Apr 2025
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Adult, Older adult
Study population: The study will include adults who are being managed for Stage 1-5 CKD or received a transplant for ESKD.
Who may be able to join
- Adult* patients at the time of enrollment with a diagnosis of CKD/ESKD by ICD-10 code in the EHR interface
- Adult * patients diagnosed and managed for CKD/ESKD invited to participate
- Ability to provide written informed consent
Who cannot join
- Death
- Manual removal (sponsor or site request)
- No EHR interface encounter > 3 years
- Engaged Cohort
- Patient expressed desire to withdraw consent to complete PROs
- Failure to complete PROs within 24 weeks of initial invitation
- Greater than 24 months lapse of survey completion after baseline surveys completed
- Additionally, the criteria detailed for Disease Cohort apply to the Engaged Cohort
About this study
TARGET-KIDNEY is an observational research study to conduct a comprehensive review of outcomes for patients with chronic kidney disease (CKD) and end-stage renal disease (ESKD).
- Conditions
- Kidney Disease, Chronic, End Stage Kidney Disease
- Being tested
- Observational
- Medical subject headings
- Renal Insufficiency, Chronic, Kidney Failure, Chronic
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
ObservationalOther
Observational
| Study group | Role | What they receive |
|---|---|---|
| Disease Cohort | Not described Receives: Other: Observational | |
| Engaged Cohort | Not described Receives: Other: Observational |
What is being measured
The primary outcome is the main question the study is designed to answer.
To characterize the natural history of disease in patients with CKD/ESKD.
Measured: 20 Years
To assess safety and effectiveness of CKD/ESKD treatments and treatments for complications of either condition
Measured: 20 Years
Secondary outcomes (3)
To evaluate provider management practices in the treatment of patients with CKD/ESKD
Measured: 20 Years
To evaluate longitudinal and patient reported outcomes in CKD/ESKD
Measured: 20 Years
To select and evaluate quality of care measures for patients with CKD/ESKD
Measured: 20 Years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted17 Mar 2023
- Study startApr 2025 (estimated)
- Primary completion7 Apr 2025
- Study completion7 Apr 2025
Why it stopped: This protocol never enrolled any paticipants
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Kidney Disease, ChronicStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Other
- Enrolment
- 0 participants (actual)
Sponsor and investigators
- Lead sponsor
- Target PharmaSolutions, Inc.
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05774392
- Sponsor's protocol ID
- TARGET-KIDNEY
- Status last verified
- Dec 2025
- First submitted
- 7 Mar 2023
- Last updated
- 17 Dec 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 17 Dec 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- An Observational Study of Patients With Chronic Kidney Disease
- ClinicalTrials.gov ID
- NCT05774392
- Acronym / sponsor ID
- TARGET-KIDNEY
- Conditions
- Kidney Disease, Chronic, End Stage Kidney Disease
- Study type
- Observational
- Recruitment status
- WithdrawnReason stopped: This protocol never enrolled any paticipants
- Enrolment
- 0 participants (actual)
- Lead sponsor
- Target PharmaSolutions, Inc.Industry (pharma, biotech, devices)
- Study start
- Apr 2025 (estimated)
- Primary completion
- 7 Apr 2025 (actual)
- Study completion
- 7 Apr 2025 (actual)
- First posted
- 17 Mar 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
TARGET-KIDNEY is an observational research study to conduct a comprehensive review of outcomes for patients with chronic kidney disease (CKD) and end-stage renal disease (ESKD).
Study design
- Observational model
- Cohort
- Time perspective
- Other
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Disease Cohort | – | Other: Observational |
| Engaged Cohort | – | Other: Observational |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Age groups
- Adult, Older adult
- Study population
- The study will include adults who are being managed for Stage 1-5 CKD or received a transplant for ESKD.
Key inclusion criteria (3 listed)
- Adult* patients at the time of enrollment with a diagnosis of CKD/ESKD by ICD-10 code in the EHR interface
- Adult * patients diagnosed and managed for CKD/ESKD invited to participate
- Ability to provide written informed consent
Key exclusion criteria (8 listed)
- Death
- Manual removal (sponsor or site request)
- No EHR interface encounter > 3 years
- Engaged Cohort
- Patient expressed desire to withdraw consent to complete PROs
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| ObservationalObservational | Other | Disease Cohort, Engaged Cohort |
Primary outcome
To characterize the natural history of disease in patients with CKD/ESKD.
Time frame: 20 Years
To assess safety and effectiveness of CKD/ESKD treatments and treatments for complications of either condition
Time frame: 20 Years
3 secondary outcomes
To evaluate provider management practices in the treatment of patients with CKD/ESKD
Time frame: 20 Years
To evaluate longitudinal and patient reported outcomes in CKD/ESKD
Time frame: 20 Years
To select and evaluate quality of care measures for patients with CKD/ESKD
Time frame: 20 Years
Results and safety
The study was withdrawn before enrolling participants, so there are no results.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 17 Dec 2025.
- Individual participant dataSharing planned: Undecided
Related trials for Kidney Disease, Chronic
Active, not recruitingPhase 2
Safety and Efficacy of Empagliflozin in Hemodialysis
End Stage Renal Disease
RecruitingPhase 3
Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients With Primary IgAN
Berger Disease, Bergers Disease
Recruiting
Investigating Vascular Properties of HEMI and SPG Signals in Individuals With or at Risk for Chronic Kidney Disease
Chronic Kidney Disease, Hypertension (HTN)
Not yet recruiting
Hypothermic Kidney Machine Perfusion With Omnisol
End Stage Renal Disease (ESRD), Kidney Transplant
Not yet recruiting
An Individuation Intervention to Reduce Socioeconomic Disparities in Chronic Kidney Disease Care
Chronic Kidney Diseases
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
Questions about this trial
What is this clinical trial studying?
An observational study of Kidney Disease, Chronic and End Stage Kidney Disease, run by Target PharmaSolutions, Inc..
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: withdrawn, as of the sponsor's last update on 17 Dec 2025. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study was withdrawn before enrolling participants, so there are no results.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
To characterize the natural history of disease in patients with CKD/ESKD. (time frame: 20 Years). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 17 Dec 2025.